Zhisheng Chen - WuXi Biologics CEO, Executive Director
| WXXWY Stock | USD 3.76 0.01 0.27% |
CEO
Dr. Zhisheng Chen was appointed as Chief Executive Officer, Executive Director of the Company. He was appointed as an executive Director and chief executive officer in February 2014 and January 2016, respectively. He is also the chairman of the Strategy Committee of the Company. Dr Chen is primarily responsible for the overall management of the business of the Group. He joined the Group in June 2011 and also serves as a director of most subsidiaries of the Company. From June 2011 to January 2016, Dr. Chen served as a senior vice president of WuXi AppTec Co., Ltd., and was responsible for the management of biologics development and manufacturing. From August 2008 to June 2011, Dr. Chen served as the chief operating officer of Shanghai Celgen Bio Pharmaceutical Co., Ltd., and was responsible for the development, manufacturing and quality control of biologics. From November 2005 to August 2008, Dr. Chen served as a director and senior engineering consultant of Eli Lilly and Company, a global pharmaceutical company listed on NYSE, and was responsible for running a clinical manufacturing facility and providing technical guidance to biologics development and manufacturing. From June 2000 to November 2005, Dr. Chen served as a process engineer and manager of Merck Co. Inc., a pharmaceutical company listed on NYSE, and was responsible for providing technical support and troubleshooting manufacturing issues of biologics and recombinant vaccines since 2016.
| Age | 50 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Web | https://www.wuxibiologics.com |
WuXi Biologics Management Efficiency
The company has return on total asset (ROA) of 0.0551 % which means that it generated a profit of $0.0551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.123 %, meaning that it generated $0.123 on every $100 dollars invested by stockholders. WuXi Biologics' management efficiency ratios could be used to measure how well WuXi Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | CEO Age | ||
| Marcio MBA | Praxis Precision Medicines | 45 | |
| Brian MD | RAPT Therapeutics | 52 | |
| Stephen Stamp | Biodexa Pharmaceticals | 62 | |
| Milton Werner | Inhibikase Therapeutics | 60 | |
| James Porter | Nuvalent | 48 | |
| Gerald Bruce | Virpax Pharmaceuticals | 67 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| Jatinder Dhaliwal | Virpax Pharmaceuticals | 36 | |
Management Performance
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 |
WuXi Biologics Leadership Team
Elected by the shareholders, the WuXi Biologics' board of directors comprises two types of representatives: WuXi Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of WuXi. The board's role is to monitor WuXi Biologics' management team and ensure that shareholders' interests are well served. WuXi Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, WuXi Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| He Wang, VP Officer | ||
| Eileen Wang, IR Senior Director | ||
| Weichang Zhou, Senior Vice President CTO, Executive Director | ||
| Ming Tu, CFO VP | ||
| Li Xiong, VP HR | ||
| Ge Li, Non-Executive Chairman of the Board | ||
| Jijie Gu, Ex Officer | ||
| Zhisheng Chen, CEO, Executive Director | ||
| Cong JD, VP Department | ||
| Tang MBA, Operations, Communications |
WuXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is WuXi Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 97.10 X | |||
| Price To Book | 6.03 X | |||
| Price To Sales | 2.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for WuXi Pink Sheet Analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.